Neural tube defects are among the most common causes of childhood mortality and disability. In its new draft recommendation, the US Preventive Services Task Force reaffirms that folic acid supplementation provides a substantial benefit for reproductive-aged women in reducing the risk of neural tube defects. The task force also highlights areas that require further study, including disparities in the prevalence of neural tube defects. We agree.
Read More »On Medical Treatments & Products
Statement of Dr. Diana Zuckerman, President, National Center for Health Research, March 8, 2023
Today the FDA announced that 19 women were reported in medical publications who developed squamous cell carcinoma (SCC) in the capsule around breast implants. This is more than the 10 women that FDA reported in September. Several of the women died. It is important to know that 24 cases of SCC have been reported to […]
Read More »Testimony of Dr. Diana Zuckerman About Jemperli (Dostarlimab) FDA Advisory Committee Meeting
February 9, 2023: Dr. Diana Zuckerman of NCHR urges the FDA Oncology Advisory Committee to require randomized trials of Jemperli for rectal cancer instead of single arm trials, so that patients and physicians can make informed decisions about the best treatment.
Read More »NCHR Comments on the CDC proposed new Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children
January 27, 2023: Hepatitis C infections have dramatically increased among pregnant women, which exposes babies during birth. National Center for Health Research supports CDC’s recommendations for HCV testing of all infants and children born to pregnant mothers with confirmed or probable HCV.
Read More »NCHR Comments on the FDA Preliminary Assessment of Potential Non-prescription Naloxone Products
January 17, 2023: NCHR agrees with the FDA’s assessment that certain types of naloxone drug products could be safe and effective for non-prescription use but training is needed to use it correctly in urgent situations. We also support FDA’s request for more research to determine how to provide the most effective instructions and labeling for non-prescription naloxone products.
Read More »